Can You Feel the Vibe Shift?
Democrats Hate Police, Love Postal Workers?
Brigitte Bardot Was Right About Islam
Let's Be Honest
Reflection on Year’s End: Infighting at TPUSA?
Trump's Yearly Performance Review
It's Morning Again in America
Frightening CCP Infiltration of the U.S. at All-Time High
Here's What Happened at Trump's Russia-Ukraine Peace Deal Presser
Justice Department Reaches Proposed Settlement With Blackstone-Owned LivCor in Rent-Price...
FBI Teases Denaturalizing, Deporting Eligible Minnesota Fraudsters
Alleged MS-13 Member Released by Activist Judge Becomes a TikToker
Five Indicted on Federal Gun Trafficking Charges in Chicago
Florida Man Wielding Salvation Army Donation Kettle Attacks Store Manager
Social Media Exposé Draws Global Attention While Minnesota Media Look Away
Tipsheet

The CDC Director Just Gave Us an Updated Vaccine Timeline

AP Photo/Alex Brandon

We've brought you a lot of exciting vaccine news these past few weeks. And there's more of it on Tuesday. Center for Disease Control Director Robert Redfield said Americans should expect a vaccine to be rolled out very, very soon. He predicted the second week of December.

Advertisement

The next question then is, who will be receiving the first doses. He answered that too.

In an interview with Fox News anchor Dana Perino, Redfield shared that the first groups to get the vaccine will probably be "nursing home residents and then some combination of health care providers and individuals at high risk for a poor outcome."

"I do think we'll have about 40 million doses of vaccine before the end of the...year," Redfield continued. "That's enough to vaccinate 20 million people. But then it will continue through January and February and hopefully by March we'll start to see vaccine available for the general public."

Advertisement

Pfizer, who vaccine its been developing with BioNTech has produced a 95 percent efficacy rate, requested an emergency authorization from the FDA. A second vaccine candidate being produced by Moderna isn't too far behind, reporting a 94 percent effectiveness. And then a third, developed by AstraZeneca, is up to 90 percent effective.

The FDA has reportedly scheduled a meeting for Dec. 10 with its Vaccines and Related Biological Products Advisory Committee to discuss Pfizer's request.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement